Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
VYNE THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 3.970 USD | -1.00% | +0.51% | +47.04% | |
| Nov. 13 | Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $114,000 | MT |
| Nov. 13 | VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
Valuation
| Fiscal Period : December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 265 | 54,6 | 8,71 | 55,4 | - | - |
| Enterprise Value (EV) 1 | 265 | 54,6 | 8,71 | 55,4 | 55,4 | 55,4 |
| P/E ratio | -0,80x | -0,72x | -0,37x | -0,82x | -1,89x | -1,81x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 12,6x | 3,70x | 18,3x | 111x | 222x | 222x |
| EV / Revenue | 12,6x | 3,70x | 18,3x | 111x | 222x | 222x |
| EV / EBITDA | - | - | - | -1,87x | -1,63x | -1,40x |
| EV / FCF | -1 933 366x | -968 444x | - | - | - | - |
| FCF Yield | 0,00% | 0,00% | - | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 2 332 | 2 973 | 3 224 | 13 957 | - | - |
| Reference price 2 | 114 | 18,4 | 2,70 | 3,97 | 3,97 | 3,97 |
| Announcement Date | 04/03/21 | 17/03/22 | 09/03/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period : December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3,60 | 0,44 | 21,0 | 14,8 | 0,48 | 0,50 | 0,25 | 0,25 |
| EBITDA 1 | -74,6 | - | - | - | - | -29,7 | -34,0 | -39,5 |
| EBIT 1 | -74,9 | -95,9 | -253 | -68,0 | -34,3 | -29,7 | -36,8 | -47,1 |
| Operating Margin | -2 083% | -21 642% | -1 203% | -461% | -7 190% | -5 940% | -14 720% | -18 820% |
| Earnings before Tax (EBT) 1 | -74,0 | -95,4 | -256 | -73,8 | -33,9 | -28,7 | -33,8 | -39,3 |
| Net income 1 | -74,2 | -95,2 | -256 | -73,3 | -23,2 | -28,7 | -33,8 | -39,3 |
| Net margin | -2 063% | -21 485% | -1 217% | -497% | -4 866% | -5 740% | -13 520% | -15 720% |
| EPS 2 | - | - | -142 | -25,6 | -7,28 | -4,82 | -2,10 | -2,19 |
| Free Cash Flow | -69,2 | -74,5 | -137 | -56,4 | - | - | - | - |
| FCF margin | -1 926% | -16 806% | -654% | -382% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 28.02.19 | 12.03.20 | 04.03.21 | 17.03.22 | 09.03.23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period : December | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4,26 | 4,09 | 2,29 | 0,18 | 0,13 | 0,17 | 0,01 | 0,10 | 0,14 | 0,11 | 0,15 |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | - | -7,30 |
| EBIT | -16,9 | -17,8 | -12,0 | -8,69 | -8,29 | -9,33 | -7,98 | -5,88 | -10,3 | - | - |
| Operating Margin | -396% | -435% | -525% | -4 883% | -6 577% | -5 589% | -133 067% | -5 934% | -7 643% | - | - |
| Earnings before Tax (EBT) 1 | -19,9 | -21,3 | -12,0 | -8,69 | -8,24 | -9,26 | -7,75 | -5,61 | -10,0 | -6,07 | -7,00 |
| Net income 1 | -19,9 | -21,3 | -11,6 | 4,67 | -8,48 | -9,46 | -9,95 | -5,62 | -10,1 | -6,58 | -7,00 |
| Net margin | -468% | -521% | -505% | 2 624% | -6 727% | -5 664% | -165 750% | -5 679% | -7 450% | -5 775% | -4 667% |
| EPS 2 | -7,02 | -7,38 | -3,96 | 1,44 | -2,70 | -2,88 | -3,33 | -1,74 | -3,09 | -2,01 | -0,50 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 08/12/21 | 11/10/21 | 03/17/22 | 05/12/22 | 08/12/22 | 11/10/22 | 03/09/23 | 05/11/23 | 08/14/23 | 11/13/23 | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period : December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -69,2 | -74,5 | -137 | -56,4 | - | - | - | - |
| ROE (net income / shareholders' equity) | -92,3% | - | - | - | - | - | - | - |
| Shareholders' equity 1 | 80,4 | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | 0,57 | 1,06 | 0,11 | - | - | - | - | - |
| Capex / CA | 15,8% | 239% | 0,54% | - | - | - | - | - |
| Announcement Date | 02/28/19 | 03/12/20 | 03/04/21 | 03/17/22 | 03/09/23 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating :
Investor Rating :
ESG Refinitiv :
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.970USD
Average target price
5.583USD
Spread / Average Target
+40.64%
EPS Revisions
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| +47.04% | 55 M $ | |
| +61.69% | 532 B $ | |
| +47.95% | 464 B $ | |
| -14.36% | 364 B $ | |
| -13.93% | 246 B $ | |
| -19.35% | 216 B $ | |
| +2.72% | 201 B $ | |
| -11.78% | 195 B $ | |
| -41.18% | 170 B $ | |
| +0.62% | 141 B $ |
- Stock
- Equities
- Stock VYNE Therapeutics Inc. - Nasdaq
- Financials VYNE Therapeutics Inc.